Progression-Free Survival – Page 2

Gilead Bolsters Trodelvy in Triple-Negative Breast Cancer With Practice-Changing Keytruda Combo Win

4 months ago talkbio0Tagged Antibody-Drug Conjugates, Combined Modality Therapy, Gilead Sciences, Immunotherapy, Keytruda, Phase 3 trial, practice-changing, Progression-Free Survival, TNBC, Triple Negative Breast Neoplasms, Trodelvy

Gilead Sciences; Trodelvy; Keytruda; triple-negative breast cancer; TNBC; antibody-drug conjugate; immunotherapy; progression-free survival; ASCO 2025; phase 3 trial; practice-changing; combination therapy

Jazz Releases Full Survival Data for Zepzelca in Lung Cancer at ASCO 2025

5 months ago talkbio0Tagged ASCO, atezolizumab, IMforte trial, Jazz, lurbinectedin, Malignant neoplasm of lung, Overall Survival, Progression-Free Survival, Small cell carcinoma of lung, Tecentriq, Zepzelca

Jazz Pharmaceuticals; Zepzelca; lurbinectedin; lung cancer; small cell lung cancer; Tecentriq; atezolizumab; IMforte trial; overall survival; progression-free survival; ASCO 2025

GSK and iTeos End Belrestotug TIGIT Program After Disappointing Lung Cancer Results

5 months ago talkbio0Tagged belrestotug, Clinical Trials, dostarlimab, Drug Development, Galaxies, immuno-oncology, iTeos, Lung-201, Malignant neoplasm of lung, Progression-Free Survival, SmithKline Beecham, TIGIT gene

GSK; iTeos; belrestotug; TIGIT; lung cancer; dostarlimab; clinical trial; drug development; GALAXIES Lung-201; immuno-oncology; progression-free survival

AstraZenecas Truqap Posts Another Pivotal Disappointment as Phase III Prostate Cancer Study Fails

5 months ago talkbio0Tagged ADT, androgen-deprivation therapy, AstraZeneca, CAPItello-280, capivasertib, Clinical Trials, Discontinuation (procedure), docetaxel, Failure (biologic function), Inhibitor, Metastatic castration-resistant prostate cancer, oncology setback, Phase 3 Clinical Trials, Progression-Free Survival, Proto-Oncogene Proteins c-akt, Radiographic, Survival, Truqap

Truqap, capivasertib, AstraZeneca, Phase III trial failure, CAPItello-280, metastatic castration-resistant prostate cancer (mCRPC), AKT inhibitor, docetaxel, androgen-deprivation therapy (ADT), oncology setback, clinical trial discontinuation, radiographic progression-free survival, overall survival

AstraZeneca, Daiichi say Enhertu delivers ‘highly statistically significant’ efficacy in first-line breast cancer

6 months ago talkbio0Tagged Antibodies, Antibody-Drug Conjugates, AstraZeneca, Daiichi, deruxtecan-nxki, Enhertu, fam-trastuzumab, first-line therapy, HER2-positive metastatic breast cancer, pertuzumab, Progression-Free Survival, Sankyo

Enhertu, fam-trastuzumab deruxtecan-nxki, AstraZeneca, Daiichi Sankyo, HER2-positive metastatic breast cancer, first-line therapy, progression-free survival, antibody drug conjugate (ADC), pertuzumab

Mixed pivotal data for Pfizer, Arvinas’ protein degrader in breast cancer

7 months ago talkbio0Tagged Clinical Trials, ESR1 gene, Improvement, Market, Pfizer, Progression-Free Survival, Statistical Significance, Vepdegestrant

Pfizer, Vepdegestrant, Clinical Trials, ESR1 gene, Statistical Significance, Improvement, Progression-Free Survival, Market

Keytruda and Lenvima Combination Shows Mixed Results in Gastroesophageal Cancer Trial

9 months ago talkbio0Tagged Clinical Trials, Endpoints, Keytruda, Lenvima, Malignant neoplasm of cardioesophageal junction of stomach, Progression-Free Survival, Survival

Keytruda, Lenvima, gastroesophageal cancer, clinical trial, survival endpoints, progression-free survival, overall survival

GSK’s Zejula-Jemperli Combination Achieves Primary Endpoint in Ovarian Cancer Trial, Falls Short on Overall Survival

10 months ago talkbio0Tagged FIRST trial, Jemperli, ovarian neoplasm, Progression-Free Survival, SmithKline Beecham, Survival, Zejula

GSK, Zejula, Jemperli, ovarian cancer, FIRST trial, progression-free survival, overall survival

Pfizer’s IBRANCE Demonstrates Significant Efficacy in HR+, HER2+ Metastatic Breast Cancer

10 months ago talkbio0Tagged Anti-HER2 therapy, Carcinoma breast stage IV, erbB-2 Receptor, Hormone Therapy, Ibrance, palbociclib, Phase 3, Progression-Free Survival, standard-of-care

IBRANCE (palbociclib), HR+/ HER2+ metastatic breast cancer, Phase 3 PATINA trial, Progression-free survival (PFS), Standard-of-care therapies, Anti-HER2 therapy, Endocrine therapy

Lilly’s Oral SERD Imlunestrant Shows Significant Progression-Free Survival Benefits in ER+, HER2- Advanced Breast Cancer

10 months ago talkbio0Tagged CDK4/6 inhibitor, ESR1 gene, Estrogen receptor positive, HER2-, Imlunestrant, Malignant neoplasm of breast, Mutation, Oral SERD, Progression-Free Survival, Verzenio

Imlunestrant, Verzenio, oral SERD, ER+, HER2-, advanced breast cancer, progression-free survival, ESR1 mutation, CDK4/6 inhibitor